Neoadjuvant Talimogene Laherparepvec for the Treatment of Metastatic Melanoma

Abstract

Get full access to this article

View all access options for this article.

References

Andtbacka

R.H.I.

, Kaufman

H.L.

, Collichio

Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.

J Clin Oncol 2015; 33: 2780–8.

Liu

B.L.

, Robinson

, Han

Z-Q

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.

Gene Ther 2003; 10: 292–303.

J.C.C.

, Coffin

R.S.

, Davis

C.J.

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

Clin Cancer Res 2006; 12: 6737–47.

Senzer

N.N.

, Kaufman

H.L.

, Amatruda

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

J Clin Oncol 2009; 27: 5763–71.